A study to find out how well a gentle laser treatment lowers eye pressure in people with glaucoma whose eye drops are no longer working

Outcomes of micropulse transscleral cyclophotocoagulation in primary open-angle and pseudoexfoliative glaucoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN62227730

Enrollment

Registered

2026-04-20

Start date

2018-10-05

Completion date

Unknown

Last updated

2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary open-angle glaucoma, pseudoexfoliative glaucoma Eye Diseases

Interventions

Micropulse transscleral cyclophotocoagulation (MP-TSCPC) using the Cyclo G6 system with MicroPulse P3 probe (Iridex Corporation) delivered at 2.0–2.2 W power, 31.3% duty cycle, for 90 seconds per hemi

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients with primary open-angle glaucoma (POAG) or pseudoexfoliative glaucoma (PEX) refractory to maximally tolerated topical medical therapy 2. Intraocular pressure above target despite maximum tolerated medical treatment 3. Scheduled for micropulse transscleral cyclophotocoagulation (MP-TSCPC) as the primary laser-surgical intervention

Exclusion criteria

Exclusion criteria: 1. Prior glaucoma surgery or laser treatment 2. Secondary glaucoma of other aetiology 3. Active ocular inflammation 4. Inability to provide informed consent

Countries

Serbia

Contacts

Public ContactMaja Zivkovic

maja.zivkovic@medfak.ni.ac.rs+381 668051551

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 11, 2026